Emicizumab-kxwh (HEMLIBRA, Genentech) was approved for use by the US Food and Drug Administration on November 16, 2017 for individuals with hemophilia A and inhibitors.
NHF's MASAC has issued the latest revision to their most comprehensive treatment document.
The designation is for people with hemophilia A without inhibitors.
NHF is expanding its work with the bleeding disorders community around the world.
ICER is an independent and non-partisan research organization that evaluates the clinical and economic value of prescription drugs, medical tests, and other healthcare and healthcare delivery innovations.
The company donated over 25 million international units (IU) of factor products used to treat hemophilia A and B.
Val D. Bias spoke to the leaders of NHF’s 52-chapter networks at the NHF 2018 Chapter Leadership Seminar in San Francisco, California.
2018 marks NHF’s 70th year as the bleeding disorders community’s chief advocate.
Applications are now open! The selected KCS recipient will receive an award of $1,000 toward their tuition costs.
Updated statement from Genentech on Hemlibra, March 28, 2018.
eNewsletter Sign Up
Steps for Living
Victory for Women
Unite for Bleeding Disorders Walk
Donate Your Car